In the RECOVERY trial - 8156 hospitalized COVID-19 patients; those on baricitinib had significantly fewer deaths (12% vs 14% PBO) but the size of benefit was somewhat smaller than that suggested by previous trials. (adjusted rate ratio 0·87) https://t.co/EW7xLc9TLC https://t.co/Ahr7bwAQmJ